Want to join the conversation?
$DHR said that coming off a historic year of M&A, the company closed six bolt-on acquisitions in 1Q16, deploying over $100MM in capital. In 1Q16, Test & Measurement segment revenue fell 5.5% with core revenues down 5%; Environmental segment revenue grew 4%, with core revenue up 3.5%; and Life Sciences & Diagnostics reported revenue was up 42%.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.